文献速递慢性肾脏病血液净化与透析

甲氧基聚乙二醇重组人促红素β与其他促红素在CKD贫血中的心血管安全性非劣效试验

Cardiovascular Safety and All-Cause Mortality of Methoxy Polyethylene Glycol-Epoetin Beta and Other Erythropoiesis-Stimulating Agents in Anemia of CKD: A Randomized Noninferiority Trial.
PubMed 文献 · Clin J Am Soc Nephrol · 2019-08-16

该多中心开放标签非劣效试验将2818例CKD贫血患者随机分配至甲氧基聚乙二醇重组人促红素β组或参照促红素组,中位随访3.4年。主要复合终点(全因死亡、非致死性心梗或卒中)发生率两组分别为45.4%和45.7%(HR 1.03,95%CI 0.93-1.15,非劣效P=0.004),全因死亡率无差异(HR 1.06,95%CI 0.94-1.19)。

要点

  • 每月一次甲氧基聚乙二醇重组人促红素β在主要心血管事件和全因死亡方面不劣于短效促红素。
  • 透析与非透析、纠正与维持治疗亚组结果与主分析一致。
  • 全因死亡率两组间无显著差异(HR 1.06,95%CI 0.94-1.19)。

核心结论

  • 在CKD贫血患者中,每月一次甲氧基聚乙二醇重组人促红素β在主要不良心血管事件或全因死亡率方面不劣于常规短效促红素。

研究设计与样本

  • 多中心、开放标签、非劣效性随机对照试验,共2818例CKD贫血患者随机接受甲氧基聚乙二醇重组人促红素β或参照促红素,按维持或纠正治疗状态及C反应蛋白水平分层。
  • 主要终点为全因死亡、非致死性心肌梗死或卒中的复合终点,由独立盲法委员会裁定,预设非劣效界值为HR 1.20。
  • 中位随访3.4年(最长8.4年),试验注册号NCT00773513。

主要发现

  • 改良意向治疗分析中,甲氧基聚乙二醇重组人促红素β组640例(45.4%)发生主要终点事件,参照组644例(45.7%),HR 1.03(95%CI 0.93-1.15),非劣效P=0.004。
  • 全因死亡率两组无差异(HR 1.06;95%CI 0.94-1.19)。
  • 透析或非透析、纠正或维持治疗亚组结果与主分析 comparable。

关键数值与推荐

  • 预设非劣效界值为主要终点HR 1.20。
  • 主要终点事件率:甲氧基聚乙二醇重组人促红素β组45.4%,参照组45.7%。
  • 全因死亡HR 1.06(95%CI 0.94-1.19)。

临床怎么用

  • 对于CKD贫血患者,每月一次甲氧基聚乙二醇重组人促红素β可作为短效促红素的替代选择,心血管安全性不劣于后者。

局限性

  • 开放标签设计可能引入偏倚。
  • 结果主要适用于与试验人群相似的CKD贫血患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Erythropoiesis-stimulating agents correct anemia of CKD but may increase cardiovascular risk. We compared cardiovascular outcomes and all-cause mortality associated with monthly methoxy polyethylene glycol-epoetin beta with those of the shorter-acting agents epoetin alfa/beta and darbepoetin alfa in patients with anemia of CKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We conducted a multicenter, open-label, noninferiority trial in which patients were randomized to receive methoxy polyethylene glycol-epoetin beta or reference erythropoiesis-stimulating agents, stratified by maintenance or correction treatment status and C-reactive protein level. The trial had a prespecified noninferiority margin of 1.20 for the hazard ratio (HR) for the primary end point (a composite of all-cause mortality, nonfatal myocardial infarction or stroke, adjudicated by an independent blinded committee). This trial is registered with ClinicalTrials.gov, number NCT00773513. RESULTS: In total, 2818 patients underwent randomization, received methoxy polyethylene glycol-epoetin beta or a reference agent, and were followed for a median of 3.4 years (maximum, 8.4 years). In the modified intention-to-treat analysis, a primary end point event occurred in 640 (45.4%) patients in the methoxy polyethylene glycol-epoetin beta arm, and 644 (45.7%) in the reference arm (HR 1.03; 95% confidence interval [95% CI], 0.93 to 1.15, P=0.004 for noninferiority). All-cause mortality was not different between treatment groups (HR 1.06; 95% CI, 0.94 to 1.19). Results in patient subgroups on dialysis or treated in the correction or maintenance settings were comparable to the primary analysis. CONCLUSIONS: In patients with anemia of CKD, once-monthly methoxy polyethylene glycol-epoetin beta was noninferior to conventional, shorter-acting erythropoiesis-stimulating agents with respect to rates of major adverse cardiovascular events or all-cause mortality.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Locatelli F, Hannedouche T, Fishbane S, et al. Cardiovascular Safety and All-Cause Mortality of Methoxy Polyethylene Glycol-Epoetin Beta and Other Erythropoiesis-Stimulating Agents in Anemia of CKD: A Randomized Noninferiority Trial. Clin J Am Soc Nephrol. 2019. PMID: 31420350. doi:10.2215/CJN.01380219

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。